Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
Abstract Background Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14714 |
| _version_ | 1797966021331517440 |
|---|---|
| author | Marco Galvez‐Nino Rossana Ruiz Katia Roque Ofelia Coanqui Natalia Valdivieso Mivael Olivera Apar Kishor Ganti Luis Mas |
| author_facet | Marco Galvez‐Nino Rossana Ruiz Katia Roque Ofelia Coanqui Natalia Valdivieso Mivael Olivera Apar Kishor Ganti Luis Mas |
| author_sort | Marco Galvez‐Nino |
| collection | DOAJ |
| description | Abstract Background Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti‐epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real‐world setting. Methods This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti‐EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS). Results We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti‐EGFR TKI as institutional treatment. ORR was 58%, after median follow‐up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006). Conclusion Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR‐activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases. |
| first_indexed | 2024-04-11T02:09:14Z |
| format | Article |
| id | doaj.art-202aadfe95434d8d9b11ab99a92b967f |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-11T02:09:14Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-202aadfe95434d8d9b11ab99a92b967f2023-01-03T02:26:19ZengWileyThoracic Cancer1759-77061759-77142023-01-01141616710.1111/1759-7714.14714Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in PeruMarco Galvez‐Nino0Rossana Ruiz1Katia Roque2Ofelia Coanqui3Natalia Valdivieso4Mivael Olivera5Apar Kishor Ganti6Luis Mas7Department of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruDepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruDepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruDepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruDepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruDepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruVA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center Omaha Nebraska USADepartment of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima PeruAbstract Background Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti‐epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real‐world setting. Methods This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti‐EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS). Results We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti‐EGFR TKI as institutional treatment. ORR was 58%, after median follow‐up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006). Conclusion Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR‐activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases.https://doi.org/10.1111/1759-7714.14714EGFRLatin Americanlung cancerreal‐worldsurvival |
| spellingShingle | Marco Galvez‐Nino Rossana Ruiz Katia Roque Ofelia Coanqui Natalia Valdivieso Mivael Olivera Apar Kishor Ganti Luis Mas Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru Thoracic Cancer EGFR Latin American lung cancer real‐world survival |
| title | Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru |
| title_full | Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru |
| title_fullStr | Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru |
| title_full_unstemmed | Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru |
| title_short | Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru |
| title_sort | real world outcomes of anti egfr therapy in advanced non small cell lung cancer egfr mutated in peru |
| topic | EGFR Latin American lung cancer real‐world survival |
| url | https://doi.org/10.1111/1759-7714.14714 |
| work_keys_str_mv | AT marcogalveznino realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT rossanaruiz realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT katiaroque realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT ofeliacoanqui realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT nataliavaldivieso realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT mivaelolivera realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT aparkishorganti realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu AT luismas realworldoutcomesofantiegfrtherapyinadvancednonsmallcelllungcanceregfrmutatedinperu |